NO20060444L - N-{4'-substituerte piperazin-1-sulfonylmetylalkyl}-N-hydroksyformamid forbindelser som metallproteinaseinhibitorer - Google Patents

N-{4'-substituerte piperazin-1-sulfonylmetylalkyl}-N-hydroksyformamid forbindelser som metallproteinaseinhibitorer

Info

Publication number
NO20060444L
NO20060444L NO20060444A NO20060444A NO20060444L NO 20060444 L NO20060444 L NO 20060444L NO 20060444 A NO20060444 A NO 20060444A NO 20060444 A NO20060444 A NO 20060444A NO 20060444 L NO20060444 L NO 20060444L
Authority
NO
Norway
Prior art keywords
alkyl
compounds
ring
aryl
sulfonylmethylalkyl
Prior art date
Application number
NO20060444A
Other languages
English (en)
Inventor
David Waterson
Maurice Raymond Verscho Finlay
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27656653&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20060444(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20060444L publication Critical patent/NO20060444L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Det beskrives forbindelser med formel (I) eller et farmasøytisk akseptabelt salt, prodrug eller solvat derav, der ring B betyr en monocyklisk arylring med seks ringatomer eller en monocyklisk heteroarylring med opp til seks ringatomer og inneholdende et eller flere ringheteroatomer der hvert heteroatom er nitrogen; R2 betyr en gruppe valgt blant C1-6 alkyl eller aryl, hvilken gruppe er substituert med en eller flere fluorgrupper; n er 1, 2 eller 3; og Rl betyr en eventuelt substituert gruppe valgt blant C1-6 alkyl, C5-7 cykloalkyl, heterocykloalkyl, aryl, heteroaryl, C1-6 alkyl-aryl, C1-6 alkyl-heteroaryl, C1-6 alkyl-cykloalkyl eller C1-6 alkyl-heterocykloalkyl. Det beskrives videre fremgangsmåter for fremstilling av forbindelsene og farmasøytiske preparater som inneholder forbindelsene. Forbindelsene finner anvendelse ved behandling av sykdomstilstander som er mediert av et eller flere metalloproteinaseenzymer.
NO20060444A 2003-06-27 2006-01-27 N-{4'-substituerte piperazin-1-sulfonylmetylalkyl}-N-hydroksyformamid forbindelser som metallproteinaseinhibitorer NO20060444L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0301922A SE0301922D0 (sv) 2003-06-27 2003-06-27 Novel compounds
PCT/GB2004/002702 WO2005000822A1 (en) 2003-06-27 2004-06-23 N-{‘4-substituted piperazine-1-sulfonylmethyl!alkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
NO20060444L true NO20060444L (no) 2006-03-22

Family

ID=27656653

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060444A NO20060444L (no) 2003-06-27 2006-01-27 N-{4'-substituerte piperazin-1-sulfonylmetylalkyl}-N-hydroksyformamid forbindelser som metallproteinaseinhibitorer

Country Status (34)

Country Link
US (1) US7485644B2 (no)
EP (1) EP1644340B1 (no)
JP (1) JP4701167B2 (no)
KR (1) KR20060026440A (no)
CN (2) CN102229589A (no)
AR (1) AR044931A1 (no)
AT (1) ATE414063T1 (no)
AU (1) AU2004251104B2 (no)
BR (1) BRPI0411929A (no)
CA (1) CA2529468A1 (no)
CO (1) CO5650254A2 (no)
CY (1) CY1108757T1 (no)
DE (1) DE602004017733D1 (no)
DK (1) DK1644340T3 (no)
ES (1) ES2315675T3 (no)
HK (1) HK1086835A1 (no)
HR (1) HRP20090009T3 (no)
IL (1) IL172615A0 (no)
IS (1) IS8257A (no)
MX (1) MXPA05013460A (no)
MY (1) MY138680A (no)
NO (1) NO20060444L (no)
NZ (1) NZ544208A (no)
PL (1) PL1644340T3 (no)
PT (1) PT1644340E (no)
RU (1) RU2351595C2 (no)
SA (1) SA04250224B1 (no)
SE (1) SE0301922D0 (no)
SI (1) SI1644340T1 (no)
TW (1) TW200524898A (no)
UA (1) UA81491C2 (no)
UY (1) UY28387A1 (no)
WO (1) WO2005000822A1 (no)
ZA (1) ZA200510458B (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0427403D0 (en) 2004-12-15 2005-01-19 Astrazeneca Ab Novel compounds I
DK1951674T3 (da) * 2005-10-26 2012-01-02 Merck Serono Sa Sulfonamidderivater og anvendelse deraf til modulation af metalloproteinaser
CN101007794B (zh) * 2006-01-26 2010-09-01 中国科学院上海药物研究所 N,n'-二取代哌嗪类衍生物及其制备方法、药物组合物和用途
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
ES2592154T3 (es) * 2010-07-08 2016-11-28 Kaken Pharmaceutical Co., Ltd. Derivado de N-hidroxiformamida y medicamento que contiene el mismo

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2317455C (en) 1998-01-30 2011-01-25 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives
GB9919776D0 (en) * 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
JP2003501414A (ja) * 1999-06-04 2003-01-14 アストラゼネカ・アクチエボラーグ メタロプロテイナーゼの阻害剤
UA73155C2 (en) * 2000-02-21 2005-06-15 Astrazeneca Ab Substituted by piperidine and piperazine n-hydroxyformamides as metalloproteinase inhibitors
GB0119472D0 (en) * 2001-08-09 2001-10-03 Astrazeneca Ab Compounds
AU2003221786A1 (en) * 2002-04-25 2003-11-10 Pharmacia Corporation Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
WO2004113312A1 (en) * 2003-06-19 2004-12-29 Celltech R & D Limited Hydroxamate sulfonamides as cd23 shedding inhibitors

Also Published As

Publication number Publication date
NZ544208A (en) 2009-02-28
SA04250224B1 (ar) 2009-05-31
AU2004251104A1 (en) 2005-01-06
ATE414063T1 (de) 2008-11-15
HRP20090009T3 (en) 2009-02-28
JP2007516164A (ja) 2007-06-21
MXPA05013460A (es) 2006-03-09
JP4701167B2 (ja) 2011-06-15
ZA200510458B (en) 2007-03-28
PL1644340T3 (pl) 2009-04-30
PT1644340E (pt) 2009-01-02
RU2005141058A (ru) 2006-07-27
US7485644B2 (en) 2009-02-03
CO5650254A2 (es) 2006-06-30
KR20060026440A (ko) 2006-03-23
MY138680A (en) 2009-07-31
US20070197542A1 (en) 2007-08-23
DK1644340T3 (da) 2009-02-02
UA81491C2 (en) 2008-01-10
WO2005000822A1 (en) 2005-01-06
SE0301922D0 (sv) 2003-06-27
EP1644340B1 (en) 2008-11-12
CA2529468A1 (en) 2005-01-06
CY1108757T1 (el) 2014-04-09
RU2351595C2 (ru) 2009-04-10
AR044931A1 (es) 2005-10-12
CN1812974B (zh) 2011-06-29
AU2004251104B2 (en) 2008-05-08
TW200524898A (en) 2005-08-01
HK1086835A1 (en) 2006-09-29
BRPI0411929A (pt) 2006-08-15
CN102229589A (zh) 2011-11-02
ES2315675T3 (es) 2009-04-01
SI1644340T1 (sl) 2009-02-28
DE602004017733D1 (de) 2008-12-24
UY28387A1 (es) 2005-01-31
CN1812974A (zh) 2006-08-02
IL172615A0 (en) 2006-04-10
EP1644340A1 (en) 2006-04-12
IS8257A (is) 2006-01-23

Similar Documents

Publication Publication Date Title
NO20062517L (no) 2-cyanopyrrolidinkarboksamidforbindelse
NO20055568L (no) Substituerte 1,4-diazepiner og anvendelser derav
NO20060444L (no) N-{4'-substituerte piperazin-1-sulfonylmetylalkyl}-N-hydroksyformamid forbindelser som metallproteinaseinhibitorer
NO20054195L (no) Isoksazolforbindelser som inhibitorer for varmesjokkproteiner
MXPA04001016A (es) Derivados de sulfonamida como inhibidores de la gamma secretasa.
TW200635585A (en) Monocyclic substituted methanones
NO20050054L (no) Nye, kondenserte imidazolderivater
MXPA05007496A (es) Tienopirimidindionas y su uso en la modulacion de enfermedades autoinmunes.
NO20074303L (no) 7-{4-[2-(2,6-diklor-4-metylfenoksy)etoksy]fenyl}-3,9-diazabisyklo-[3.3.1]non-6-en-6-karboksylsyresyklopropyl-(2,3-dimetylbenzyl)amid som renininhibitor til behandling av hypertensjon
NO20063330L (no) Amidderivater med en syklopropylaminokarbonylsubstituent som er nyttige som cytokininhibitorer
NO20050612L (no) Pyrrolidinderivater som oksytocinantagonister
EA200500717A1 (ru) Новые соединения имидазопиридина, способ их получения и фармацевтические композиции, которые их содержат
NO20032731L (no) Fremgangsmåte for fremstilling av sulfonamid-substituerte imidazotriazinoner
EA200401519A1 (ru) N- ациламинобензольные производные в качестве селективных ингибиторов моноаминооксидазы b
EA199900057A1 (ru) Ингибиторы матриксных металлопротеиназ
NO20063111L (no) Fremgangsmate for fremstilling av tiazolpyrimidiner
BR0205683A (pt) Processo para a preparação de derivados de piperazina, e, mesilato de um composto
NO20082226L (no) 6-heteroarylpyridoindolonderivater, deres fremstilling og terapeutisk anvendelse derav
NO176176B (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive arylsulfonamider
Gao et al. Synthesis of functionalized 5-substituted thiazolidine-2-thiones via adscititious xanthate-promoted radical cyclization of allyl (alkyl/aryl) dithiocarbamates
NO20055924L (no) Metode for fremstilling av (2s)-3-(4- {2-[Amino]-2-Oksoetoksy}Fenyl)-2-Etoksypropansyrederivater
AR021968A1 (es) Oximas e hidrazonas sustituidas como antagonistas de neuroquinina
NO20000373D0 (no) Nye cyano-indol serotinin-reopptaks-inhibitorforbindelser, fremgangsmåte for deres fremstilling og farmasoeytiske sammensetninger inneholdende dem
DK169517B1 (da) [Aryl](3-pyridinyl)methanon,oximderivater samt fremgangsmåde til fremstilling deraf
NO20065057L (no) benzoksazociner og terapeutisk anvendelse derav som monoamin reopptaks inhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application